Biodistribution Study of 188Re-Labeled Trisuccin-HuCC49 and Trisuccin-HuCC49ΔCH2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer Xenografts

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages

  Safavy, Ahmad ^a   Khazaeli, M B ^b   Safavy, Kamellia ^b   Mayo, Matthew S ^c   Buchsbaum, Donald J ^a  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CHELATING AGENT; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUCC49 RE 188; RHENIUM 188; TRISUCCIN; UNCLASSIFIED DRUG; HYDROXAMIC ACID; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM; SUCCINIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; RAT; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLON TUMOR; HUMAN; METABOLISM; MOUSE; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; HUMANS; HYDROXAMIC ACIDS; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; SUCCINATES; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 85024289183     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Buchsbaum, D. J., Langmuir, V. K., and Wessels, B. W. Experimental radioimmunotherapy. Med. Phys., 20: 551-567, 1993.
2. Yarranton, G. Antibodies as carriers for drugs and radioisotopers. In: W. J. Harris and J. R. Adasir (eds.), Antibody Therapeutics, pp. 53-72. Boca Raton, FL: CRC Press, 1997.
3. Buchsbaum, D. J. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 115-140. Boca Raton, FL: CRC Press, 1995.
4. Waldmann, T. A. Monoclonal antibodies in diagnosis and therapy. Science (Washington DC), 252: 1657-1662, 1991.
5. Goldenberg, D. M., Sharkey, R. M., Goldenberg, H., Hall, T. C., Murthy, S., Izon, D. O., Gascon, P., and Swayne, L. C. Monoclonal antibody therapy of cancer. N. J. Med., 87: 913-918, 1990.
6. Wahl, R. L. Experimental radioimmunotherapy: a brief overview. Cancer (Phila.), 73: 989-992, 1994.
7. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
8. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
9. Wilbur, D. S. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem., 3: 433-470, 1992.
10. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. A., Morgan, A. C., Reno, J. M., and Fritzberg, A. R. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med., 30: 216-226, 1989.
11. Khawli, L. A., and Kassis, A. I. Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies. Int. J. Radiat. Appl. Instrum. B, 16: 727-733, 1989.
12. Vaidyanathan, G., and Zalutsky, M. R. Radioiodination of antibodies via. N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. Bioconjug. Chem., 1: 387-393, 1990.
13. Schuster, J. M., Garg, P. K., Bigner, D. D., and Zalutsky, M. R. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res., 51: 4164-4169, 1991.
14. Ali, S. A., Eary, J. F., Warren, S. D., Badger, C. C., and Krohn, K. A. Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies. Int. J. Radiat. Appl. Instrum. B, 15: 557-561, 1988.
15. Buchegger, F., Vacca, A., Carrel, S., Schreyer, M., and Mach, J. P. Radioimmunotherapy of human colon carcinoma by 131I-labeled monoclonal anti-CEA antibodies in a nude mouse model. Int. J. Cancer, 41: 127-134, 1988.
16. Rainsbury, R., and Westwood, J. Tumour localization with monoclonal antibody radioactivity labelled with metal chelate rather than iodine. Lancet, 2: 1347-1348, 1982.
17. Hagan, P. L., Halpern, S. E., Chen, A., Krishnan, L., Frincke, J., Bartholomew, R. M., David, G. S., and Carlo, D. In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J. Nucl. Med., 26: 1418-1423, 1985.
18. Kievit, E., van Gog, F. B., Schluper, H. M., van Dongen, G. A., Pinedo, H. M., and Boven, E. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys., 38: 813-823, 1997.
19. DeNardo, S. J., Kukis, D. L., Miers, L. A., Winthrop, M. D., Kroger, L. A., Salako, Q., Shen, S., Lamborn, K. R., Gumerlock, P. H., Meares, C. F., and DeNardo, G. L. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J. Nucl. Med., 39: 842-849, 1998.
20. Schubiger, P. A., Alberto, R., and Smith, A. Vehicles, chelators, and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug. Chem., 7: 165-179, 1996.
21. Srivastava, S. C., and Mease, R. C. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Nucl. Med. Biol., 18: 589-603, 1991.
22. Griffiths, G. L., Goldenberg, D. M., Jones, A. L., and Hansen, H. J. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjug Chem, 3: 91-99, 1992.
23. Knapp, F. F., Jr. Rhenium-188: a generator-derived radioisotope tbr cancer therapy. Cancer Biother. Radiopharm., 13: 337-349, 1998.
24. Kotts, C. E., Su, F. M., Leddy, C., Dodd, T., Scates, S., Shalaby, M. R., Wirth, C. M., Giltinan, D., Schroff, R. W., Fritzberg, A. R., Shepard, H. M., Slamon, D. J., and Hutchins, B. M. 186Re-labeled antibodies to p185 HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother. Radiophann, 11: 133-144, 1996.
25. Eary, J. F. Fundamentals of radioimmunotherapy. Chem. Rev., 18: 105-108, 1991.
26. Jurisson, S., Berning, D., Jia, W., and Ma, D. Coordination compounds in nuclear medicine. Chem. Rev., 93: 1137-1156, 1993.
27. Fritzberg, A. R., Abrams, P. G., Beaumier, P. L., Kasina, S., Morgan, A. C., Rao, T. N., Reno, J. M., Sanderson, J. A., Srinivasan, A., Wilbur, D. S., and Vanderheyden, J. L. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc. Natl. Acad. Sci. USA, 85: 4025-4029, 1988.
28. Najafi, A., Alauddin, M. M., Sosa, A., Ma, G. Q., Chen, D. C., Epstein, A. L., and Siegel, M. E. The evaluation of 186Re-labeled antibodies using N2S4 chelate in vitro and in vivo using tumor-bearing nude mice. Int. J. Radiat. Appl. Instrum. B, 19: 205-212, 1992.
29. Schultze, L. M., Todaro, L. J., Baldwin, R. M., Byrne, E. F., and McBride, B. J. Synthesis, characterization, and crystal structure of neutral rhenium (V) complexes with S-substituted N2S2 ligands. Inorg. Chem., 33: 5579-5585, 1994.
30. Gerretsen, M., Visser, G. W., van Walsum, M., Meijer, C. J., Snow, G. B., and van Dongen, G. A. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res., 53: 3524-3529, 1993.
31. Safavy, A., Buchsbaum, D. J., and Khazaeli, M. B. Synthesis of N-[ tris [ 2-[ [ N-(benzy loxy )amino ]carbon yl ]ethyl ]methyl] succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. Bioconjug. Chem., 4: 194-198, 1993.
32. Safavy, A., Sanders, A., Qin, H., and Buchsbaum, D. J. Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]-methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol. Bioconjug. Chem., 8: 766-771, 1997.
33. Safavy, A., Khazaeti, M. B., Kirk, M., Coward, L., and Buchsbaum, D. J. Further studies on the protein conjugation of hydoxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. Bioconjug. Chem., 10: 18-23, 1999.
34. Muraro, R., Kuroki, M., Wunderlich, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res., 48: 4588-4596, 1988.
35. Kashmiri, S. V. S., Shu, L., Padlan, E. A., Milenic, D. E., Schlom, J., and Horan Hand, P. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma, 14: 461-473, 1995.
36. LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A. M., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., and Khazaeli, M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
37. Meredith, R. F., LoBuglio, A. F., Plott, W. E., Orr, R. A., Brezovich, I. A., Russell, C. D., Harvey, E. B., Yester, M. V., Wagner, A. J., Spencer, S. A., Wheeler, R. H., Saleh, M. N., Rogers, K. J., Polansky, A., Salter, M. M., and Khazaeti, M. B. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgGI, 17-1A monoclonal antibody. J. Nucl. Med., 32: 1162-1168, 1991.
38. Slavin-Chiorini, D. C., Kashmiri, S. V. S., Lee, H.-S., Milenic, D. E., Poole, D. J., Bemon, E., Schlom, J., and Horan Hand, P. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother. Radiopharm., 12: 305-316, 1997.
39. Knapp, F. F., Jr., and Mirzadeh, S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur. J. Nucl. Med., 21: 1151-1165, 1994.
40. Kamioki, H., Mirzadeh, S., Lambrecht, R. M., Knapp, R., and Dadachova, K. 188W to 188Re generator for biomedical applications. Radiocbimica Acta, 65: 39-46, 1994.
41. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, J. P. A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
42. Eckelman, W. C., and Steigman, J. Direct labeling with 99mTc. Int. J. Radiat. Appl. Instrum. B, 18: 3-7, 1991.
43. Juweid, M., Sharkey, R. M., Swayne, L. C., Griffiths, G. L., Dunn, R., and Goldenberg, D. M. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J. Nucl. Med., 39: 34-42, 1998.
44. Gagliardi, E., and Raber, H. Hydroxamsauren als analytische reagentien. Monatsh. Chem., 93: 360-368, 1962.
45. Bauer, L., and Exner, O. The chemistry of hydroxamic acids and hydroxyimides. Angew Chem. Int. Ed. Engl., 13: 376, 1974.
46. Fournie-Zaluski, M.-C., Coulaud, A., Bouboutou, R., Chaillet, P., Devin, J., Waksman, G., Costentin, J., and Roques, P. New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties. J. Med. Chem., 28: 1158-1169, 1985.
47. Shao, J., and Tam, J. P. Unprotected peptides as building blocks for the synthesis of peptide. J. Am. Chem. Soc., 117: 3893-3899, 1995.
48. Slavin-Chiorini, D. C., Kashmiri, S. V. S., Schlom, J., Calvo, B., Shu, L. M., Schott, M. E., Milenic, D. E., Snoy, P., Carrasquillo, J., Anderson, K., and Horan Hand, P. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. (Suppl), 55: 5957s-5967s, 1995.
49. Slavin-Chiorini, D. C., Horan Hand, P., Kashmiri, S. V. S., Calvo, B., Zaremba, S., and Schlom, J. Biologic properties of a CH2 domaindeleted recombinant immunoglobulin. Int. J. Cancer, 53: 97-103, 1993.
50. Mueller, B. M., Reisfeld, R. A., and Gillies, S. D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc. Natl. Acad. Sci. USA, 87: 5702-5705, 1990.